Related Experiment Video
Updated: Jun 10, 2026
07:41
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
Published on: March 1, 2022
Reversibility of left ventricular dysfunction resulting from chemotherapy: can this be expected?
Quinn S Wells1, Daniel J Lenihan
1Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN, USA.
Progress in Cardiovascular Diseases
|August 24, 2010
Summary
Cancer survivors face increased cardiovascular risks. Early detection and intervention are key to managing chemotherapy-induced cardiomyopathy, improving outcomes for cancer patients.
Area of Science:
- Oncology
- Cardiology
- Cardio-oncology
Background:
- Advances in cancer treatment have led to improved long-term survival rates.
- Increased longevity in cancer survivors is associated with a rise in cardiovascular disease and treatment-related cardiotoxicity.
- Chemotherapy-induced left ventricular dysfunction was historically considered difficult to treat and associated with poor prognosis.
Purpose of the Study:
- To re-evaluate the prognosis and treatment of chemotherapy-related cardiomyopathy in light of contemporary heart failure therapies.
- To highlight the importance of early detection and prompt intervention for managing chemotherapy-induced cardiotoxicity.
- To advocate for advanced risk stratification and monitoring strategies in cardio-oncology.
Main Methods:
- Review of recent data and clinical trials predating current heart failure management protocols.
- Emphasis on integrating symptom detection, noninvasive imaging, and biomarkers for monitoring.
- Proposal for a multidisciplinary approach involving cardiologists and oncologists.
Main Results:
- Selected forms of chemotherapy-related cardiomyopathy may be reversible with timely intervention.
- Treatment response is contingent upon early identification and prompt management.
- Contemporary heart failure therapies offer new possibilities for managing cardiotoxicity.
Conclusions:
- Chemotherapy-induced cardiomyopathy is not uniformly resistant to therapy and can be reversible.
- Sophisticated risk stratification, monitoring (including imaging and biomarkers), and early intervention are crucial.
- A collaborative, multidisciplinary team approach is essential for optimal care of cancer patients with cardiovascular complications.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...